Yogaprol 25 Tablet ER contains Metoprolol Succinate 23.75 mg, a selective beta-1 adrenergic receptor blocker used primarily in the management of cardiovascular conditions. This extended-release formulation ensures a gradual and sustained release of the active ingredient, promoting stable plasma concentrations and improving patient compliance through once-daily dosing. Metoprolol Succinate exerts its therapeutic effect by reducing heart rate, myocardial contractility, and cardiac output, thereby decreasing blood pressure and myocardial oxygen demand. It is indicated for the treatment of hypertension, angina pectoris, and heart failure, as well as for the prevention of myocardial infarction and management of certain arrhythmias. Yogaprol 25 Tablet ER should be administered under medical supervision, with dosage adjustments based on clinical response and tolerance. Caution is advised in patients with bradycardia, heart block, or severe peripheral arterial disease. Common adverse effects include fatigue, dizziness, and gastrointestinal disturbances. Abrupt discontinuation should be avoided to prevent exacerbation of angina or precipitating myocardial infarction. Regular monitoring of blood pressure, heart rate, and cardiac function is recommended during therapy. Yogaprol 25 Tablet ER offers an effective and convenient option for long-term management of cardiovascular disorders requiring beta-blockade.